Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study
Table 2
Demographic and clinical characteristics of the two groups.
Variables
Group A: stage 2 ()
Group B: stage 3 ()
values
No.
%
No.
%
Sex
Male
16
51.6
16
55.2
0.782
Female
15
48.4
13
44.8
Age (years)
Range
61-89
60-85
0.403
Smoking
12
38.7
15
51.7
0.311
Primary diseases
Breast cancer
3
9.7
5
17.2
Multiple myeloma
3
9.7
4
13.9
Prostate cancer
10
32.3
2
6.9
Pulmonary cancer
8
25.7
9
31.0
Renal cancer
0
0
4
13.9
Lymphoma
0
0
1
3.4
Gastric carcinoma
1
3.2
0
0
Rectum carcinoma
0
0
1
3.4
Unknown cancer
0
0
1
3.4
Osteoporosis
6
19.4
2
6.9
General diseases
Hypertension
15
48.4
12
41.4
0.586
Diabetes
8
25.8
10
34.5
0.464
Renal disease
2
6.5
5
17.2
0.247
Local factors
Tooth extraction
21
67.7
22
75.9
0.485
Denture use
7
22.6
3
10.3
0.302
Periodontal disease
27
87.1
24
82.8
0.727
Chemotherapy
11
35.5
21
72.4
0.004
Targeted drugs
7
22.6
16
55.2
0.009
Endocrine drugs
13
41.9
7
24.1
0.144
Immunosuppressive drugs
4
12.9
8
27.6
0.155
Lesion location
Mandible
25
80.6
18
62.1
0.111
Maxilla
6
19.4
15
51.7
0.009
Anterior region
4
12.9
5
17.2
0.727
Posterior region
27
87.1
24
82.8
0.727
TTO (months)
Range
16-120
11-72
0.144
dTTO (months)
Range
0-36
0-21
0.710
values were statistically significant. Abbreviations: SD: standard deviation; TTO: time from first using bisphosphonate to the onset of MRONJ; dTTO: time from last using bisphosphonate to the onset of MRONJ.
